Semaglutide
Ozempic / Wegovy
GLP-1 receptor agonist that revolutionized obesity treatment. FDA-approved medication with extensive clinical data.
Key Facts: Semaglutide
Category
Weight Loss & Metabolic
Evidence
Approved
Availability
Prescription
Protocols
4
Half-Life
~7 days
Routes
subcutaneous · oral
Research Overview & Mechanisms
Mimics GLP-1 action, reducing appetite through delayed gastric emptying and central hypothalamic signaling.
Reported Research Benefits
Available Protocols
Frequently Asked Questions
FAQ
Clinical Evidence
Approved by regulatory agencies (FDA/EMA) with extensive Phase III clinical trial data.
200
studies
150
human
Regulatory Status
Leading GLP-1 drug with extensive clinical evidence from STEP/SUSTAIN trials.
Known Interactions
Compare Semaglutide
Scientific Sources & Further Reading
Explore peer-reviewed research about Semaglutide:
External links open in new tabs. Always verify information with qualified healthcare providers.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →